Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Carcinoma of Breast
Interventions: DRUG: Trastuzumab
Sponsor: Celltrion
Collaborators: Nippon Kayaku Co., Ltd.